Functional response, in T2 severe asthmatic patients, treated with mepolizumab for 2 years. Bonavia M, Bondi B, Bagnasco D, Napoli L, et al. J Asthma 2026 Mar 21:1-9. doi: 10.1080/02770903.2026.2645698.

Read + Share

Amedeo Smart

Independent Medical Education

Bonavia M, Bondi B, Bagnasco D, Napoli L, et al. Functional response, in T2 severe asthmatic patients, treated with mepolizumab for 2 years. J Asthma 2026 Mar 21:1-9. doi: 10.1080/02770903.2026.2645698.
PMID: 41863282